ATE470665T1 - Cycloalkylaminderivate als inhibitoren der wechselwirkung zwischen mdm2 und p53 - Google Patents

Cycloalkylaminderivate als inhibitoren der wechselwirkung zwischen mdm2 und p53

Info

Publication number
ATE470665T1
ATE470665T1 AT07727060T AT07727060T ATE470665T1 AT E470665 T1 ATE470665 T1 AT E470665T1 AT 07727060 T AT07727060 T AT 07727060T AT 07727060 T AT07727060 T AT 07727060T AT E470665 T1 ATE470665 T1 AT E470665T1
Authority
AT
Austria
Prior art keywords
mdm2
interaction
cycloalkylamin
inhibitors
derivatives
Prior art date
Application number
AT07727060T
Other languages
German (de)
English (en)
Inventor
Jean Lacrampe
Christophe Meyer
Bruno Schoentjes
Alain Poncelet
Camille Wermuth
Bruno Giethlen
Jean-Marie Contreras
Muriel Joubert
Hijfte Luc Van
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of ATE470665T1 publication Critical patent/ATE470665T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT07727060T 2006-03-22 2007-03-19 Cycloalkylaminderivate als inhibitoren der wechselwirkung zwischen mdm2 und p53 ATE470665T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06111529 2006-03-22
US78512006P 2006-03-23 2006-03-23
PCT/EP2007/052582 WO2007107545A1 (en) 2006-03-22 2007-03-19 Cyclic-alkylaminederivatives as inhibitors of the interaction between mdm2 and p53

Publications (1)

Publication Number Publication Date
ATE470665T1 true ATE470665T1 (de) 2010-06-15

Family

ID=38110050

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07727060T ATE470665T1 (de) 2006-03-22 2007-03-19 Cycloalkylaminderivate als inhibitoren der wechselwirkung zwischen mdm2 und p53

Country Status (8)

Country Link
US (2) US8088795B2 (enExample)
EP (1) EP1999126B1 (enExample)
JP (1) JP5162574B2 (enExample)
AT (1) ATE470665T1 (enExample)
AU (1) AU2007228784B2 (enExample)
CA (1) CA2644649C (enExample)
DE (1) DE602007007065D1 (enExample)
WO (1) WO2007107545A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2007004244A0 (en) 2005-05-10 2007-12-31 Intermune Inc Method of modulating stress-activated protein kinase system
US8288377B2 (en) 2007-09-21 2012-10-16 Janssen Pharmaceutica N.V. Inhibitors of the interaction between MDM2 and p53
EP2296653B1 (en) 2008-06-03 2016-01-27 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
EA021883B1 (ru) 2009-02-04 2015-09-30 Янссен Фармацевтика Нв Производные индола в качестве противораковых агентов
US8658170B2 (en) 2010-01-06 2014-02-25 Joseph P. Errico Combination therapy with MDM2 and EFGR inhibitors
US20130149314A1 (en) 2010-02-09 2013-06-13 Jörn Bullerdiek p19Arf, HMGA2 and MDM2 For Use in the Diagnosis and Treatment of Aberrant Cell Growth
WO2012012653A1 (en) * 2010-07-21 2012-01-26 Errico Joseph P Combination therapy with mdm2 and efgr inhibitors
FR2967072B1 (fr) 2010-11-05 2013-03-29 Univ Dundee Procede pour ameliorer la production de virus et semences vaccinales influenza
WO2012065182A2 (en) * 2010-11-12 2012-05-18 University Of Massachusetts Modulation of ubiquitination of synaptic proteins for the treatment of neurodegenerative and psychiatric disorders
SI2640467T1 (sl) * 2010-11-19 2015-04-30 Novartis Ag Kristalinična oblika inhibitorja interakcije MDM2/4 in P53
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
US9719970B2 (en) 2012-11-30 2017-08-01 Waters Technologies Corporation Methods and apparatus for the analysis of vitamin D metabolites
WO2014100065A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
CN105492011A (zh) 2013-04-08 2016-04-13 丹尼斯·M·布朗 不理想给药化学化合物的治疗增效
DK3102576T3 (da) 2014-02-03 2019-07-22 Vitae Pharmaceuticals Llc Dihydropyrrolopyridininhibitorer af ror-gamma
RU2692485C2 (ru) 2014-04-02 2019-06-25 Интермьюн, Инк. Противофиброзные пиридиноны
MY195016A (en) 2014-08-04 2023-01-03 Nuevolution As Optionally Fused Heterocyclyl-Substituted Derivatives of Pyrimidine Useful for The Treatment of Inflammatory, Metabolic, Oncologic and Autoimmune Diseases
SI3207043T1 (sl) 2014-10-14 2019-04-30 Vitae Pharmaceuticals, Inc. Dihidropirolopiridinovi inhibitorji za ROR-gama
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
WO2016181414A1 (en) * 2015-05-12 2016-11-17 Council Of Scientific & Industrial Research Process for the synthesis of ivacaftor and related compounds
EP3331876B1 (en) 2015-08-05 2020-10-07 Vitae Pharmaceuticals, LLC Modulators of ror-gamma
EP3364972A1 (en) * 2015-10-23 2018-08-29 Daiichi Sankyo Company, Limited Dosage regimen of mdm2 inhibitor for treating cancers
EP3868750A1 (en) 2015-11-20 2021-08-25 Vitae Pharmaceuticals, LLC Modulators of ror-gamma
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
TWI757266B (zh) 2016-01-29 2022-03-11 美商維它藥物有限責任公司 ＲＯＲ－γ調節劑
CN109152843A (zh) 2016-05-20 2019-01-04 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
AU2017315343A1 (en) 2016-08-24 2019-02-28 Arqule, Inc. Amino-pyrrolopyrimidinone compounds and methods of use thereof
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA
CN115716826A (zh) 2017-07-24 2023-02-28 生命医药有限责任公司 RORγ的抑制剂
AU2020405446A1 (en) 2019-12-20 2022-05-26 Nuevolution A/S Compounds active towards nuclear receptors
BR112022012205A2 (pt) 2019-12-20 2022-09-13 Nuevolution As Compostos ativos para receptores nucleares
JP7713954B2 (ja) 2020-03-31 2025-07-28 ヌエヴォリューション・アクティーゼルスカブ 核内受容体に対して活性な化合物
CA3174252A1 (en) 2020-03-31 2021-10-07 Nuevolution A/S Compounds active towards nuclear receptors
WO2022183006A1 (en) 2021-02-25 2022-09-01 Mayo Foundation For Medical Education And Research Compounds for programmable protein degradation and methods of use for the disease treatment
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO863197A0 (en) 1997-08-18 1997-09-11 Fujisawa Pharmaceutical Co., Ltd. Novel derivatives
GB9819860D0 (en) 1998-09-12 1998-11-04 Zeneca Ltd Chemical compounds
US6309492B1 (en) 1998-09-16 2001-10-30 Marc A. Seidner Polymer fill coating for laminate or composite wood products and method of making same
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
WO2000032175A2 (en) 1998-12-02 2000-06-08 Pfizer Products Inc. METHODS AND COMPOSITIONS FOR RESTORING CONFORMATIONAL STABILITY OF A PROTEIN OF THE p53 FAMILY
NZ524421A (en) 2000-09-15 2005-02-25 Anormed Inc Chemokine receptor binding heterocyclic compounds
ES2566056T3 (es) 2001-03-29 2016-04-08 Eli Lilly And Company N-(2-ariletil)bencilaminas como antagonistas del receptor 5-HT6
EP1403255A4 (en) * 2001-06-12 2005-04-06 Sumitomo Pharma RHO KINASE INHIBITORS
US20030149038A1 (en) * 2001-11-09 2003-08-07 The Regents Of The University Of California Alpha-helix mimicry by a class of organic molecules
CN1596114A (zh) 2001-11-13 2005-03-16 三维药物公司 取代的1,4－苯并二氮杂䓬类及其在治疗癌症中的应用
KR100650966B1 (ko) 2001-12-18 2006-11-30 에프. 호프만-라 로슈 아게 시스-2,4,5-트리페닐-이미다졸린 및 종양 치료에서의 그의용도
GB0215650D0 (en) 2002-07-05 2002-08-14 Cyclacel Ltd Bisarylsufonamide compounds
GB0419481D0 (en) * 2004-09-02 2004-10-06 Cancer Rec Tech Ltd Isoindolin-1-one derivatives
MX2007003375A (es) * 2004-09-22 2007-05-07 Janssen Pharmaceutica Nv Inhibidores de la interaccion entre mdm2 y p53.

Also Published As

Publication number Publication date
CA2644649C (en) 2014-06-17
JP5162574B2 (ja) 2013-03-13
US20120071508A1 (en) 2012-03-22
EP1999126B1 (en) 2010-06-09
AU2007228784B2 (en) 2012-03-08
EP1999126A1 (en) 2008-12-10
AU2007228784A1 (en) 2007-09-27
CA2644649A1 (en) 2007-09-27
US20100168163A1 (en) 2010-07-01
WO2007107545A1 (en) 2007-09-27
US8088795B2 (en) 2012-01-03
DE602007007065D1 (de) 2010-07-22
US8377961B2 (en) 2013-02-19
JP2009530345A (ja) 2009-08-27

Similar Documents

Publication Publication Date Title
DE602007007065D1 (de) Cycloalkylaminderivate als inhibitoren der wechselwirkung zwischen mdm2 und p53
ATE547415T1 (de) Inhibitoren der wechselwirkung zwischen mdm2 und p53
SG155941A1 (en) Inhibitors of the interaction between mdm2 and p53
ATE542799T1 (de) Chinolinonderivate als parp und tank-inhibitoren
JO2704B1 (en) Interference inhibition factors between MD2 and B53
IL185275A0 (en) N-sulphonylpyrrole derivatives and pharmaceutical compositions containing the same
SG154433A1 (en) Phthalazine derivatives as parp inhibitors
TW200616978A (en) Quinazolinone derivatives as parp inhibitors
EA200500203A1 (ru) Новый способ синтеза и новая кристаллическая форма агомелатина и фармацевтические композиции, которые её содержат
ATE432272T1 (de) Aminophenylderivate als neue inhibitoren von histondeacetylase
MX2010010406A (es) Tetrahidrofenantridinonas y tetrahidrociclopentaquinolinonas como inhibidores de la polimerizacion de poli(adp-ribosa)polimerasa-1 y tubulina.
EA200700185A1 (ru) Производные хиназолиндиона в качестве ингибиторов parp
ATE547395T1 (de) Aminopropanol-derivate als modulatoren des sphingosin-1-phosphat-rezeptors
ATE539073T1 (de) Heterocyclylalkylderivate als neue inhibitoren von histondeacetylase
BRPI0508966A (pt) composto, composição farmacêutica, e, uso de um composto
EA201200891A1 (ru) Производные 3,4,4a,10d-тетрагидро-1h-тиопирано[4,3-c]изохинолина
ATE533759T1 (de) Imidazolinon- und hydantoinderivate als neue inhibitoren von histondeacetylase
ATE513818T1 (de) Chinazolinonderivate als tubulinpolymerisationshemmer
NO20082185L (no) Heterocykliske CETP-inhibitorer
EA200801145A1 (ru) Спироциклические производные хиназолина в качестве ингибиторов pde7
NO20080839L (no) Isotopsubstituerte protonpumpeinhibitorer
EA200801366A1 (ru) Производные 3,6-дигидро-2-оксо-6н-1,3,4-тиадиазина
EA200870157A1 (ru) Производные 2-карбамид-4-фенилтиазола, их получение и их применение в терапии

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties